000 01159 a2200313 4500
005 20250515234050.0
264 0 _c20100825
008 201008s 0 0 eng d
022 _a1469-493X
024 7 _a10.1002/14651858.CD008169.pub2
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBatterink, Josh
245 0 0 _aSpironolactone for hypertension.
_h[electronic resource]
260 _bThe Cochrane database of systematic reviews
_cAug 2010
300 _aCD008169 p.
_bdigital
500 _aPublication Type: Journal Article; Meta-Analysis; Review; Systematic Review
650 0 4 _aAntihypertensive Agents
_xadverse effects
650 0 4 _aBlood Pressure
_xdrug effects
650 0 4 _aCross-Over Studies
650 0 4 _aHumans
650 0 4 _aHypertension
_xdrug therapy
650 0 4 _aRandomized Controlled Trials as Topic
650 0 4 _aSpironolactone
_xadverse effects
700 1 _aStabler, Sarah N
700 1 _aTejani, Aaron M
700 1 _aFowkes, Curt T
773 0 _tThe Cochrane database of systematic reviews
_gno. 8
_gp. CD008169
856 4 0 _uhttps://doi.org/10.1002/14651858.CD008169.pub2
_zAvailable from publisher's website
999 _c20025722
_d20025722